Calithera Biosciences, Inc.: Nasdaq/NYSE listing notice — Calithera to dissolve; Nasdaq delisting effective Feb 2, 2023 after 'public shell' determination

Calithera Biosciences, Inc.

Board approved dissolution and liquidation plan on Jan 9, 2023, subject to stockholder approval.
Company discontinuing all clinical programs and terminating most employees by end of Q1.
Nasdaq notified Calithera it is a 'public shell'; company will not appeal the determination.
Trading of common stock to be suspended as of Feb 2, 2023; Nasdaq to file Form 25-NSE to delist.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Calithera Biosciences, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101

Exact text from the filing

January 24, 2023, we received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising us that based upon Nasdaq’s review and pursuant to Listing Rule 5101, Nasdaq believes that we are a “public shell,” and that the continued listing of our securities is no longer warranted. We will not appeal Nasdaq’s determination. Therefore, we expect, based on Nasdaq’s written notice, that the trading of our common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove our

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-014684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.